Metallothionein Activation and Zinc Intake

Mechanism and Timeline

Metallothionein remains activated and functional as long as zinc intake continues, with enterocyte turnover occurring approximately every 2-6 days, at which point the copper-metallothionein complex is shed into fecal contents 1
Zinc induces enterocyte metallothionein synthesis, which then preferentially binds copper over zinc due to its higher affinity for copper 1
The protein persists throughout the lifespan of the enterocyte (approximately 2-6 days in normal turnover) 1
Once bound to copper, the metallothionein-copper complex is lost into fecal contents as enterocytes are naturally shed 1

For therapeutic efficacy, zinc must be taken at least twice daily, though three times daily is preferred (150 mg elemental zinc divided into three doses for adults >50 kg) 1, 2
Metallothionein activation is not a one-time event but requires continuous zinc presence 1
Taking zinc with food interferes with absorption and reduces effectiveness 1, 3
Optimal absorption requires taking zinc 30 minutes before meals 3

Zinc also induces hepatocellular metallothionein, providing a secondary mechanism for copper management beyond the intestinal effect 1

The serum copper value reflects true copper status based on body stores and ceruloplasmin-bound copper, and timing of the blood draw relative to zinc intake does not matter for assessing copper status 4, 5, 6
Therapeutic zinc doses (150 mg/day in divided doses for Wilson disease) require monitoring both serum copper and 24-hour urinary copper to prevent overtreatment, as recommended by the American Association for the Study of Liver Diseases 4, 5, 6

Chronic zinc supplementation (especially doses >30-50 mg/day for several weeks) can genuinely lower serum copper due to the metallothionein-mediated absorption blockade, and 24-hour urinary copper should be <75 µg/day, indicating effective copper blockade 4, 5, 6
Studies show that 50 mg zinc daily for 6 weeks can decrease copper-dependent enzyme activity (erythrocyte Cu,Zn-superoxide dismutase), suggesting early copper depletion, and patients on zinc therapy should be monitored regularly 4, 5, 6

Zinc stimulates enterocyte production of metallothionein, a cysteine‑rich protein that binds copper with roughly ten‑fold greater affinity than zinc, thereby limiting copper entry into the portal circulation. 7
Metallothionein sequesters copper within intestinal cells; the bound copper is lost in the feces as enterocytes are naturally shed every 2–6 days, preventing systemic copper overload. 7
When zinc intake is insufficient, metallothionein synthesis falls dramatically, removing this protective barrier and allowing markedly increased copper absorption and accumulation. 7

Zinc therapy is used in Wilson’s disease to create a negative copper balance by continuously blocking both dietary copper absorption and re‑absorption of endogenously secreted copper via sustained metallothionein induction. [8][7]